Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics, Inc. (NASDAQ: NMRA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $18.00.